RE:RE:RE:RE:RE:RE:RE:RE:CellPress: Emerging Field of OV Based Cancer ImmunotherapyLike yourself JohnnyYeg, I think that Matt has focused his attention on expanding pelareorep's use in in combination with anti-PD-L1 immune checkpoint inhibitors like Roche/Genentech's atezolizumab and AstraZeneca's durvalumab, for example.
Both Roche and AstraZeneca are visibly working in the development of breast and GI cancer treatments, particularly since Astrazeneca is partnered with Daichii Sanyo with the ADC Enhertu in the treatment of metastatic breast cancer, which would benefit from the addition of an immune checkpoint inhibitor, except that Enhertu is unable to remodel and prepare the TME in advance of the addition of a checkpoint inhibitor.
ONCY's pelareorep is capable of affecting this task, and has demonstrated that pelareorep is able to remodel an otherwise immunosuppressive TME and upregulate/activate CD8+ T cells.Pelareorep's synergistic combination with immune checkpoint inhibitors and other I/O agents such as bispecifics and ADCs is particularly beneficial when patients relapse on ADCs like Enhertu following treatment for metastatic breast cancer. Additionally, ONCY's Phase 2 Goblet-1 basket study has demonstrated pelareorep is synergistic with Roche's anti-PD-L1 atezolizumab (Tecentriq) in the treatment of GI cancers, such as pancreatic, and anal cancer.
https://oncolyticsbiotech.com/press_releases/oncolytics-biotech-initiates-enrollment-expansion-of-goblet-anal-cancer-cohort/
Data from the pancreatic cohort in the Goblet Phase 1/2 cancer study showed a correlation between the expansion of TIL-specific clones and tumor response, which provides compelling support for the use of pelareorep-based therapies in immunologically “cold” tumors. In particular, these data, along with the impressive clinical results, support the ability of pelareorep-checkpoint inhibitor combination therapies to meaningfully improve treatment responses in diseases like pancreatic cancer that have resisted immune-based therapeutic approaches.
https://stockhouse.com/companies/bullboard?symbol=t.onc&postid=35885855
Big Pharma companies with ADCs have seen ONCY data's from the PDAC arm of the GOBLET study (pelareorep + chemotherapy + immune checkpoint inhibitor - atezolizumab), that was presented on October 2023 showed a 62% objective response rate (ORR), 7.2 months of median progression-free survival (mPFS), interim median overall survival (mOS) of 10.6 months, and expansion of both pre-existing and new T-cell clones.
ONCY's Phase 2 Bracelet-1 in advanced/metastatic breast cancer demonstrated that pelareorep is effective as a monotherapy in combination with the standard of care of chemotherapy versus standard of care alone. This Phase 2 study demonstrates that ONCY's pelareorep can be effectively combined with an ADC carrying a chemotherapeutical payload.
ONCY's Phase 2 AWARE-1 biomarker study prepared the way for the next wave of immunotherapeutic advances.
https://stockhouse.com/companies/bullboard/oncy/oncolytics-biotech-ord-shs?postid=34100933
https://oncolyticsbiotech.com/press_releases/oncolytics-biotech-announces-key-progress-and-upcoming-studies-for-breast-and-pancreatic-cancer-treatments-prepares-for-fda-accelerated-approval-path/
Since pelareorep has been proven to activate TiLs, specifically CD8+ dendritic cells, and has shown it capability to remodels the tumor microenvironment, which both facilitates and synergizes the addition of an immune checkpoint inhibitor, the combination of pelareorep + immune checkpoint inhibitor is ready for combination with an ADC carrying a chemotherapeutical payload .
https://stockhouse.com/companies/bullboard?symbol=t.onc&postid=35887631
Now ONCY has expanded pelareorep's reach into benefitting liver cancer treatment when combined with a PD-L1 immune checkpoint inhibitor, such as Roche's Tecentriq or AstraZeneca's Imfinzi - which can be potentially extrapolated into combination with ADCs/bispecifics. Furthermore, this benefit can be achieved with a single dose of pelareorep, which is less toxic to the liver base cells than other forms of I/O treatment.
https://oncolyticsbiotech.com/wp-content/uploads/2024/10/Oncolytics-Deck-Oct-2024-v2.pdf